Skip to main content

Large CROs Stand Out in Post-marketing Pharmacovigilance

By September 24, 2018December 20th, 2021No Comments

Informing pharmaceutical drug developers, manufacturers, and service providers. Raleigh, N.C. – September 24, 2018 – Industry Standard Research (ISR) has released a new report, the 10th edition of its CRO Quality Benchmarking – Phase IV Service Providers seriesISR surveyed 230 decision-makers at sponsor organizations to gather their insights on topics such as service provider brand perceptions and use, selection drivers, and performance evaluation.

“Outsourced Phase IV projects require service providers with specific skill sets,” states Kevin Olson, CEO of Industry Standard Research. “For example, our research often shows that Cost and Technology are greater drivers in late phase work than earlier in the development cycle.”

In response to customer feedback, ratings on 13 individual study types like compassionate use studies and comparative effectiveness research are new additions to this year’s report. These allow sponsors to easily gauge which CROs have performed well in the necessary capacities.

This year, inVentiv Health Clinical (now part of Syneos Health), Covance, and IQVIA stood out for their performance in for Post-marketing Pharmacovigilance studies.

ISR uses respondents’ Brand and Performance ratings to index providers’ positions relative to each other:

  • Brand Index – Primarily intended for use by service marketers, the Brand Index reflects the strength of a company’s brand across three measures of pure perception: Awareness, Familiarity, and Leadership.
  • Performance Index – This index reflects the entirety of a company’s performance scores—from all users, across all attributes and services—relative to its customers’ expectations. Sponsors evaluating CROs can use this metric to assess how performance against customer expectations varies between CROs in their consideration set. Service providers can understand how their organization fares relative to the competition.

Olson explains, “Survey respondents were asked to assess service providers they had worked with in the past 18 months across 6 critical attributes and 14 study types. The result is a comprehensive analysis of 30 CROs, with 11 service providers receiving in-depth one-page profiles in the report.”

For more information on ISR’s CRO Quality Benchmarking – Phase IV Service Providers (10th Edition) report, please visit ISR’s report pageAbout Industry Standard Research Industry Standard Research is the premier, full-service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s Web site at, email, or follow ISR on Twitter @ISRreports.